Skip to main content
BOTANIX PHARMACEUTICALS LTD logo

BOTANIX PHARMACEUTICALS LTD — Investor Relations & Filings

Ticker · BOT ISIN · AU000000BOT2 ASX Manufacturing
Open in API
Filings indexed 1,209 across all filing types
Latest filing 2019-11-24 Capital/Financing Update
Country AU Australia
Listing ASX BOT

About BOTANIX PHARMACEUTICALS LTD

https://botanixpharma.com/

Botanix Pharmaceuticals Ltd is a clinical-stage pharmaceutical company focused on the development and commercialization of novel topical treatments for serious skin conditions. The company utilizes its proprietary Permetrex™ skin delivery technology, which is designed to improve the delivery of active ingredients through the skin. Its primary product, Sofdra™ (sofpironium bromide), is an FDA-approved prescription topical gel for the treatment of primary axillary hyperhidrosis. The company's research and development pipeline also includes clinical-stage candidates for the treatment of acne, rosacea, and atopic dermatitis. Botanix aims to address significant unmet medical needs in dermatology by providing innovative therapeutic solutions with enhanced safety and efficacy profiles.

Recent filings

Filing Released Lang Actions
Botanix Announces De-scheduling of Synthetic CBD 3 pages 514.0KB
Capital/Financing Update Classification · 90% confidence The document is an ASX/Media Release dated 25 November 2019 announcing the de-scheduling of synthetic CBD by the US DEA, which impacts the company's manufacturing and clinical development activities. It discusses regulatory changes, supply agreements, and clinical study progress but does not contain financial statements, detailed financial results, or management analysis. It is a corporate announcement about regulatory and operational developments rather than a financial report or detailed investor presentation. The document length is 7690 characters, which is moderate but the content is clearly an announcement of a regulatory and operational update. Therefore, the most appropriate classification is Capital/Financing Update (CAP) as it relates to changes affecting the company's product development and supply chain costs, which impact capital and financing considerations.
2019-11-24 English
Botanix presents at Dermatology Drug Development Summit 22 pages 2.4MB
Investor Presentation Classification · 95% confidence The document is an ASX/Media Release dated 21 November 2019 from Botanix Pharmaceuticals. It announces the company's presentation at the Dermatology Drug Development Summit, highlighting their dermatology pipeline and clinical development progress. The text includes a detailed investor presentation with product information, team bios, technology explanation, and clinical pipeline status. There are no financial statements, earnings data, or regulatory filings such as 10-K or interim reports. The document is a detailed presentation aimed at investors and stakeholders, focusing on strategy, product development, and market positioning. Therefore, it fits the definition of an Investor Presentation (IP). The document length is substantial (15,000 characters), supporting it being a full presentation rather than a brief announcement or summary.
2019-11-20 English
Appendix 4C - Quarterly 10 pages 397.2KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Botanix Pharmaceuticals Quarterly Activities Report and 4C Quarterly Cash Flow Report' and is dated 31 October 2019. It discusses clinical study progress, financial cash flow, corporate updates, and operational highlights for the quarter ended 30 September 2019. The content includes detailed financial and operational data for a period shorter than a full fiscal year, specifically a quarter. It is not a brief announcement or a presentation but a comprehensive quarterly report with substantive financial and operational information. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2019-10-30 English
Annual General Meeting Presentation 23 pages 2.2MB
AGM Information Classification · 100% confidence The document is titled 'Botanix Pharmaceuticals 2019 Annual General Meeting Presentation' and is dated 28 October 2019. It explicitly states that it is a presentation to be made at the Annual General Meeting (AGM). The content includes company overview, clinical data, pipeline updates, and near-term catalysts, which are typical for an AGM presentation. There is no indication that this is a full annual report, earnings release, or other regulatory filing. The document length is substantial (15,000 characters), consistent with a detailed presentation rather than a brief announcement. Therefore, the document fits the category of AGM Information (AGM-R).
2019-10-27 English
Results of Meeting 2 pages 141.8KB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Results of Annual General Meeting' and dated 28 October 2019. It provides detailed poll results and proxy vote summaries for resolutions passed at the AGM, including re-election of directors, adoption of remuneration report, and ratification of placements. The content focuses on the official voting outcomes from the shareholder meeting rather than the meeting materials or presentations themselves. The document length is under 5,000 characters and it is a formal announcement of voting results, not the AGM presentation or the full annual report. Therefore, it fits the category of 'Declaration of Voting Results & Voting Rights Announcements' (DVA).
2019-10-27 English
BTX 1503 Acne Phase 2 Study Results Presentation 14 pages 969.5KB
Investor Presentation Classification · 95% confidence The document is an ASX/Media Release dated 23 October 2019 from Botanix Pharmaceuticals Limited. It provides detailed information about the Phase 2 study results of BTX 1503 for acne, including safety, efficacy, study design, endpoints, and statistical data. The content is a presentation of clinical trial results rather than a formal regulatory filing or financial report. It is not an Annual Report, Interim Report, Earnings Release, or any other financial or regulatory filing. The document is a detailed presentation aimed at investors and the public to communicate clinical trial outcomes and company progress. Therefore, it fits best under the category of Investor Presentation (IP). The document length (15,000 characters) and detailed data support this classification with high confidence.
2019-10-22 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.